The global RNA therapeutics market commands a multi-billion-dollar valuation and represents one of the fastest-growing sectors in modern pharmacology and biotechnology. Driven by rapid advancements in messenger RNA vaccines, RNA interference, antisense oligonucleotides, and precision gene-editing tools, market analysts project exponential expansion over the coming decade as more targeted genetic medicines successfully clear clinical trials and receive commercial regulatory approvals for rare and chronic diseases.